Inozyme Pharma (NASDAQ:INZY) Stock, Quote.Headers.trade-ideas

Inozyme Pharma

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

Pharmaceutics,Laboratory:,Pipette,Dropping,Yellow,Liquid,Into,Test,Tubes,,Medical

Biotech

News

Health Care

Movers

Trading Ideas

General

INZY

Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701&#39;s potential to treat rare diseases like ENPP1 and ABCC6 deficiencies.

Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock &#39;Could Be Worth A Look&#39;

xr:d:DAFpQHWcfko:2,j:5894483215029085173,t:23072108

Initiation

Markets

Analyst Ratings

RKLB

This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Nikola Motor

Intraday Update

ALTS

ALZN

APDN

APPS

CING

CLOV

FFIE

FHTX

FUBO

GNLN

GOVX

IBRX

LLAP

LQDA

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NKLA

SEEL

SIDU

SOND

TELO

TGTX

TNXP

TOVX

VALN

VRAX

XPER

ZVRA

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Inozyme Pharma Inc

<a href="https://asia.nikkei.com/Business/Business-deals/Honda-Nissan-talks-on-merger-ratio-may-start-at-5-to-1-Nikkei-analysis" title="https://asia.nikkei.com/Business/Business-deals/Honda-Nissan-talks-on-merger-ratio-may-start-at-5-to-1-Nikkei-analysis">https://asia.nikkei.com/Business/Business-deals/Honda-Nissan-talks-on-merger-ratio-may-start-at-5-to-1-Nikkei-analysis</a>

NSANY

'Honda-Nissan talks on merger ratio may start at 5-to-1: Nikkei analysis' - Nikkei

Deep-pocketed investors have adopted a bullish approach towards BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BBAI usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 32 extraordinary options activities for BigBear.ai Hldgs. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 46% bearish. Among these notable options, 3 are puts, totaling $75,075, and 29 are calls, amounting to $2,330,271.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $1.0 to $7.0 for BigBear.ai Hldgs over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for BigBear.ai Hldgs's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of BigBear.ai Hldgs's whale activity within a strike price range from $1.0 to $7.0 in the last 30 days. 
<h3>BigBear.ai Hldgs Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735243232_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BBAI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$2.4</td>
<td>$2.3</td>
<td>$2.3</td>
<td>$3.50</td>
<td>$219.6K</td>
<td>9.6K</td>
<td>6.6K</td>
</tr>
<tr>
<td>BBAI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$2.9</td>
<td>$2.6</td>
<td>$2.9</td>
<td>$2.00</td>
<td>$209.6K</td>
<td>1.6K</td>
<td>2.7K</td>
</tr>
<tr>
<td>BBAI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$2.8</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$3.50</td>
<td>$141.0K</td>
<td>9.6K</td>
<td>8.3K</td>
</tr>
<tr>
<td>BBAI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$2.85</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$2.00</td>
<td>$140.0K</td>
<td>1.6K</td>
<td>836</td>
</tr>
<tr>
<td>BBAI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$2.55</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$3.50</td>
<td>$131.0K</td>
<td>9.6K</td>
<td>633</td>
</tr>
</tbody>
</table>

<h3>About BigBear.ai Hldgs</h3>
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains &amp; logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber &amp; Engineering segment and Analytics segment.
Following our analysis of the options activities associated with BigBear.ai Hldgs, we pivot to a closer look at the company's own performance.
<h3>Current Position of BigBear.ai Hldgs</h3>
<ul>
<li>Trading volume stands at 93,999,331, with BBAI's price up by 21.59%, positioned at $4.54.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 70 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest BigBear.ai Hldgs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

BBAI

BigBear.ai Hldgs Unusual Options Activity

High-rolling investors have positioned themselves bullish on SoFi Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SOFI often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 38 options trades for SoFi Techs. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 39% bearish. Among all the options we identified, there was one put, amounting to $40,332, and 37 calls, totaling $2,193,077.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.0 to $30.0 for SoFi Techs during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for SoFi Techs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of SoFi Techs's whale trades within a strike price range from $7.0 to $30.0 in the last 30 days. 
<h3>SoFi Techs Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735243227_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$3.7</td>
<td>$3.6</td>
<td>$3.67</td>
<td>$16.00</td>
<td>$213.1K</td>
<td>5.5K</td>
<td>643</td>
</tr>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.0</td>
<td>$1.98</td>
<td>$2.01</td>
<td>$17.00</td>
<td>$200.9K</td>
<td>10.4K</td>
<td>1.4K</td>
</tr>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$5.45</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$20.00</td>
<td>$159.0K</td>
<td>14.0K</td>
<td>1.5K</td>
</tr>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.97</td>
<td>$2.9</td>
<td>$2.9</td>
<td>$15.00</td>
<td>$145.8K</td>
<td>13.1K</td>
<td>503</td>
</tr>
<tr>
<td>SOFI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.1</td>
<td>$3.7</td>
<td>$4.05</td>
<td>$12.00</td>
<td>$111.7K</td>
<td>30.6K</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About SoFi Techs</h3>
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
Having examined the options trading patterns of SoFi Techs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of SoFi Techs</h3>
<ul>
<li>Trading volume stands at 26,370,003, with SOFI's price up by 3.87%, positioned at $16.64.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 32 days.</li>
</ul>
<h3>Expert Opinions on SoFi Techs</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $13.666666666666666.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Underperform, setting a price target of $12. 
&#x2A; An analyst from JP Morgan has decided to maintain their Neutral rating on SoFi Techs, which currently sits at a price target of $16. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Underweight rating for SoFi Techs, targeting a price of $13. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest SoFi Techs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

SOFI

Behind the Scenes of SoFi Techs's Latest Options Trends

Financial giants have made a conspicuous bullish move on DraftKings. Our analysis of options history for DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) revealed 17 unusual trades.
Delving into the details, we found 70% of traders were bullish, while 17% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $533,320, and 9 were calls, valued at $479,040.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $55.0 for DraftKings over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for DraftKings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DraftKings's whale activity within a strike price range from $35.0 to $55.0 in the last 30 days. 
<h3>DraftKings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735243222_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DKNG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$39.00</td>
<td>$293.4K</td>
<td>674</td>
<td align="right">65</td>
</tr>
<tr>
<td>DKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$7.2</td>
<td>$7.1</td>
<td>$7.2</td>
<td>$40.00</td>
<td>$75.6K</td>
<td>439</td>
<td align="right">115</td>
</tr>
<tr>
<td>DKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.97</td>
<td>$2.85</td>
<td>$2.97</td>
<td>$55.00</td>
<td>$59.4K</td>
<td>22.8K</td>
<td align="right">1</td>
</tr>
<tr>
<td>DKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.96</td>
<td>$2.85</td>
<td>$2.96</td>
<td>$55.00</td>
<td>$59.3K</td>
<td>22.8K</td>
<td align="right">401</td>
</tr>
<tr>
<td>DKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.96</td>
<td>$2.86</td>
<td>$2.96</td>
<td>$55.00</td>
<td>$59.2K</td>
<td>22.8K</td>
<td align="right">811</td>
</tr>
</tbody>
</table>

<h3>About DraftKings</h3>
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in about 30 states and iGaming in seven states, with both products available to around 40% of Canada's population. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.
Having examined the options trading patterns of DraftKings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is DraftKings Standing Right Now?</h3>
<ul>
<li>With a volume of 3,279,598, the price of DKNG is down -0.13% at $38.52. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 49 days.</li>
</ul>
<h3>What The Experts Say On DraftKings</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $53.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on DraftKings, which currently sits at a price target of $53. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DraftKings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

DKNG

DraftKings Options Trading: A Deep Dive into Market Sentiment

Canaccord Genuity analyst Joseph Vafi maintains Payfare (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PAY#TSX">PAY</a>) with a Hold and raises the price target from C$2 to C$4.

Price Target

TSX:PAY

Canaccord Genuity Maintains Hold on Payfare, Raises Price Target to C$4

After suffering a recent earnings miss combined with a challenging economic backdrop, shares of recreational vehicle provider Winnebago Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) have printed gobs of red ink over the trailing month. Nevertheless, historical data reveals that investors tend to view bouts of unusual volatility as a buying opportunity, thus making the case for bullish speculation.
First, one of the main contributors to the downside in WGO stock centers on the underlying company's fiscal-first-quarter results. Winnebago <a href="https://www.benzinga.com/news/earnings/24/12/42615254/winnebago-industries-stock-falls-after-q1-earnings-miss-amid-challenging-marine-operating-environment">reported an adjusted loss per share of 3 cents</a>, badly missing analysts' consensus view of 20 cents. Further, revenue slipped 18% on a year-over-year basis to $625.6 million, also missing the estimated target of $672.232 million.
Second, management provided additional context, but this failed to bolster investor confidence. "As expected, the RV and marine operating environment remained challenging in the first quarter, marked by subdued consumer demand and a cautious dealer network reluctant to make significant commitments on new orders ahead of the historically slow winter season," said President and CEO Michael Happe.
Nevertheless, the head executive stated that the company anticipates a rise in demand as the RV and marine markets enter the more sales-friendly spring season. To be fair, <a href="https://www.benzinga.com/24/12/42654183/is-winnebago-industries-steering-towards-a-turnaround-in-h2-analysts-are-split">analyst views on a turnaround for WGO stock are split</a>. However, a fundamental argument for upside speculation does exist.
Also Read: <a href="https://www.benzinga.com/24/12/42689806/netflix-to-release-beyonce-bowl-nfl-halftime-performance-as-standalone-special">Netflix To Release &#8216;Beyoncé Bowl&#8217; NFL Halftime Performance As Standalone Special</a>
<h2 class="wp-block-heading">Historical Trends Favor WGO Stock as a Value Play</h2>
Under normal market circumstances, Winnebago stock tends to carry a neutral trajectory. Specifically, over the trailing five years, the odds that on any given Friday, WGO would generate a positive return relative to Monday's opening price comes in at 50.2%. This figure is calculated by dividing the number of positive weeks over the total number of weeks in the dataset (i.e. last five years).
However, this baseline metric doesn't reveal the emotional shifts in sentiment that may occur during periods of unusual volatility. In other words, pricing events that extend multiple standard deviations below the mean could impact the fear-greed continuum much more greatly than normal market sessions. Therefore, data-driven investors may be better served with a Bayesian inference to calculate conditional probabilities.
Last week, WGO stock lost 9.49% of its market value, which is a rare occurrence. In the past five years, there have only been 14 instances (not including last week) where WGO lost 9.49% or worse. Interestingly, eight of the following weeks saw a positive return or a success ratio of 57.14%.
Additional context makes Winnebago even more enticing. Four of the weekly losses totaling 9.49% or worse occurred in February and March of 2020. Presumably, most investors agree that COVID-19 represents a unique market impact that's unlikely to materialize again anytime soon.
Taking out the impact of COVID-19, the success ratio improves to 70%, with 10 weeks seeing a loss of 9.49% or worse and seven of the following weeks resulting in a positive return.
<h2 class="wp-block-heading">A Bull Call Spread Beckons</h2>
Considering investors&#8217; tendency to buy the dip in WGO stock, speculators may want to consider <a href="https://www.benzinga.com/money/bull-spread#:~:text=A%20bull%20call%20spread%20involves,expires%20on%20the%20same%20date.">bull call spreads</a> of Winnebago shares. This options strategy involves buying a call and simultaneously selling a call, both for the same expiration date. The idea is to take the credit from the short call to partially offset the debit paid for the long call, thus discounting the long position.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="374" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135830/WGO-stock-options-chain-1024x374.jpg" alt="" class="wp-image-708024" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135830/WGO-stock-options-chain-1024x374.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135830/WGO-stock-options-chain-300x110.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135830/WGO-stock-options-chain-768x281.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135830/WGO-stock-options-chain-1536x562.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26135830/WGO-stock-options-chain.jpg 1578w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
For WGO stock, the next available options chain expires on Jan. 17, 2025. Given the skepticism surrounding Winnebago's business and comeback intentions, market makers are currently providing attractive pricing for bull call spreads.
For example, the Jan. 17 47.50/50.00 bull call spread — buy the $47.50 call, simultaneously sell the $50 call — carries a net debit of $125 after applying the options multiplier. Should WGO stock hit or exceed the short call strike price of $50, the payout is the difference between the strike prices minus the net debit paid or $125.
In other words, within a few weeks, bullish speculators have the opportunity to pocket a 100% payout. That's an enticing proposition, given that, statistically, investors tend to load the boat when WGO stock encounters unusually steep volatility.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42688941/are-us-vehicles-under-30000-a-thing-of-the-past-trumps-mexico-tariff-plans-could-change-auto-market">Are Sub-$30,000 Cars Disappearing? Trump&#8217;s Tariff Plans Could Reshape US Auto Market</a></li>
</ul>
Photo: Jonathan Weiss/Shutterstock.com

Earnings Misses

Long Ideas

Options Corner: Winnebago's Implosion Could Signal A Comeback Opportunity

Whales with a lot of money to spend have taken a noticeably bearish stance on Neumora Therapeutics.
Looking at options history for Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $581,375 and 6, calls, for a total amount of $245,900.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $15.0 for Neumora Therapeutics over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Neumora Therapeutics options trades today is 7461.43 with a total volume of 6,284.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Neumora Therapeutics's big money trades within a strike price range of $5.0 to $15.0 over the last 30 days.
<h3>Neumora Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735242345_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMRA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.35</td>
<td>$1.15</td>
<td>$1.45</td>
<td>$5.00</td>
<td>$378.0K</td>
<td>15.1K</td>
<td>3.1K</td>
</tr>
<tr>
<td>NMRA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$3.79</td>
<td>$12.50</td>
<td>$77.4K</td>
<td>7.6K</td>
<td>246</td>
</tr>
<tr>
<td>NMRA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$5.7</td>
<td>$5.0</td>
<td>$5.5</td>
<td>$10.00</td>
<td>$55.0K</td>
<td>8</td>
<td>100</td>
</tr>
<tr>
<td>NMRA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.4</td>
<td>$2.25</td>
<td>$2.25</td>
<td>$7.50</td>
<td>$44.4K</td>
<td>8.2K</td>
<td>211</td>
</tr>
<tr>
<td>NMRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.3</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$12.50</td>
<td>$40.0K</td>
<td>7.6K</td>
<td>414</td>
</tr>
</tbody>
</table>

<h3>About Neumora Therapeutics</h3>
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
In light of the recent options history for Neumora Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Neumora Therapeutics's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 422,366, the NMRA's price is up by 1.03%, now at $10.74. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 70 days.</li>
</ul>
<h3>What The Experts Say On Neumora Therapeutics</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $30.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $30.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Neumora Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

NMRA

This Is What Whales Are Betting On Neumora Therapeutics

Financial giants have made a conspicuous bullish move on e.l.f. Beauty. Our analysis of options history for e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 22% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $697,100, and 6 were calls, valued at $298,944.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $115.0 to $200.0 for e.l.f. Beauty during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of e.l.f. Beauty stands at 123.67, with a total volume reaching 796.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in e.l.f. Beauty, situated within the strike price corridor from $115.0 to $200.0, throughout the last 30 days.
<h3>e.l.f. Beauty Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735242340_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$18.9</td>
<td>$18.5</td>
<td>$18.6</td>
<td>$130.00</td>
<td>$558.0K</td>
<td align="right">174</td>
<td align="right">300</td>
</tr>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.7</td>
<td>$6.6</td>
<td>$6.7</td>
<td>$132.00</td>
<td>$81.0K</td>
<td align="right">1</td>
<td align="right">145</td>
</tr>
<tr>
<td>ELF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$69.8</td>
<td>$68.3</td>
<td>$69.8</td>
<td>$200.00</td>
<td>$69.8K</td>
<td align="right">40</td>
<td align="right">0</td>
</tr>
<tr>
<td>ELF</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$70.1</td>
<td>$68.6</td>
<td>$69.3</td>
<td>$200.00</td>
<td>$69.3K</td>
<td align="right">40</td>
<td align="right">20</td>
</tr>
<tr>
<td>ELF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$26.5</td>
<td>$26.2</td>
<td>$26.5</td>
<td>$140.00</td>
<td>$55.7K</td>
<td align="right">82</td>
<td align="right">42</td>
</tr>
</tbody>
</table>

<h3>About e.l.f. Beauty</h3>
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan and cruelty-free cosmetics and skin care products. The Company's mission is to make the best of beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women which include eyeliner, mascara, false eyelashes, lipstick, the foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels. The products that the company sells are marketed under the e.l.f. Cosmetics, W3LL PEOPLE and Keys Soulcare brands. It carries out sales within the US and internationally, out of which maximum revenue is generated from the US.
Following our analysis of the options activities associated with e.l.f. Beauty, we pivot to a closer look at the company's own performance.
<h3>Where Is e.l.f. Beauty Standing Right Now?</h3>
<ul>
<li>With a trading volume of 353,827, the price of ELF is down by -0.16%, reaching $131.7.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 40 days from now.</li>
</ul>
<h3>What Analysts Are Saying About e.l.f. Beauty</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $165.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from DA Davidson persists with their Buy rating on e.l.f. Beauty, maintaining a target price of $170. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for e.l.f. Beauty, targeting a price of $150. 
&#x2A; Maintaining their stance, an analyst from DA Davidson continues to hold a Buy rating for e.l.f. Beauty, targeting a price of $170. 
&#x2A; An analyst from DA Davidson persists with their Buy rating on e.l.f. Beauty, maintaining a target price of $170. 
&#x2A; In a cautious move, an analyst from Goldman Sachs downgraded its rating to Buy, setting a price target of $165. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest e.l.f. Beauty options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

e.l.f. Beauty Unusual Options Activity For December 26

Deep-pocketed investors have adopted a bearish approach towards Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LRCX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Lam Research. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 30% leaning bullish and 40% bearish. Among these notable options, 12 are puts, totaling $585,068, and 8 are calls, amounting to $1,196,232.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $54.0 to $164.0 for Lam Research over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Lam Research stands at 793.58, with a total volume reaching 4,701.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lam Research, situated within the strike price corridor from $54.0 to $164.0, throughout the last 30 days.
<h3>Lam Research Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735242335_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.45</td>
<td>$5.15</td>
<td>$5.25</td>
<td>$85.00</td>
<td>$787.5K</td>
<td align="right">627</td>
<td>1.5K</td>
</tr>
<tr>
<td>LRCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.85</td>
<td>$8.75</td>
<td>$8.85</td>
<td>$68.00</td>
<td>$172.5K</td>
<td align="right">72</td>
<td>0</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/03/25</td>
<td>$10.95</td>
<td>$10.75</td>
<td>$10.84</td>
<td>$85.00</td>
<td>$54.2K</td>
<td align="right">0</td>
<td>350</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$93.7</td>
<td>$89.65</td>
<td>$90.05</td>
<td>$164.00</td>
<td>$54.0K</td>
<td align="right">0</td>
<td>6</td>
</tr>
<tr>
<td>LRCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/03/25</td>
<td>$11.15</td>
<td>$10.4</td>
<td>$10.8</td>
<td>$85.00</td>
<td>$54.0K</td>
<td align="right">0</td>
<td>200</td>
</tr>
</tbody>
</table>

<h3>About Lam Research</h3>
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
<h3>Lam Research's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,523,239, the price of LRCX is up by 0.7%, reaching $74.35.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 27 days from now.</li>
</ul>
<h3>What The Experts Say On Lam Research</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $82.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Lam Research, maintaining a target price of $83. 
&#x2A; An analyst from Bernstein has decided to maintain their Market Perform rating on Lam Research, which currently sits at a price target of $85. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Lam Research with a target price of $78. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lam Research options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

LRCX

Smart Money Is Betting Big In LRCX Options

Insider Trades

SKYH

Sky Harbour Group: Rozek Alexander Buffett (Director) Buys 152,486 @ Avg Price: $9.50

U.S. stocks traded slightly lower toward the end of trading, with the S&amp;P 500 edging lower on Thursday.
The Dow traded down 0.03% to 43,283.94 while the NASDAQ fell 0.05% to 20,021.98. The S&amp;P 500 also fell, dropping, 0.07% to 6,035.54.
Check This Out: <a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Industrials shares rose by 0.3% on Thursday.
In trading on Thursday, consumer discretionary shares dipped by 0.5%.
Top Headline
U.S. initial jobless claims fell by 1,000 from the previous week to a reading of 219,000 during the second week of December, compared to market estimates of 224,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares shot up 48% to $8.08. On Thursday, SEALSQ announced the launch of SEALQUANTUM.com Lab, a research hub designed to help businesses transition to quantum-safe encryption</li>
<li>Shares of SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>)got a boost, surging 117% to $0.4801 after the company announced it received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) shares were also up, gaining 75% to $2.50 after it reported a 43% year-on-year increase in November bookings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Neuphoria Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEUP#NASDAQ">NEUP</a>) shares dropped 32% to $4.52.</li>
<li>Shares of Baosheng Media Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) were down 42% to $4.14.</li>
<li>SaverOne 2014 Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) was down, falling 33% to $1.0148.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $69.98 while gold traded up 0.5% at $2,649.10.
Silver traded up 0.2% to $30.335 on Thursday, while copper rose 0.7% to $4.1375.
Euro zone
In Europe, markets in Germany, France, London, Spain and Switzerland are closed for the Boxing Day holiday.
European shares were higher today. The eurozone's STOXX 600 gained 0.17%, Germany's DAX fell 0.18% and France's CAC 40 rose 0.14%. Spain's IBEX 35 Index rose 0.33%, while London's FTSE 100 rose 0.42%.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 gaining 1.12%, China's Shanghai Composite Index gaining 0.14% and India's BSE Sensex falling 0.01%.
Economics
U.S. initial jobless claims fell by 1,000 from the previous week to a reading of 219,000 during the second week of December, compared to market estimates of 224,000.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42684254/top-3-utilities-stocks-youll-regret-missing-in-december">Top 3 Utilities Stocks You&#8217;ll Regret Missing In December</a></li>
</ul>

Equities

Eurozone

Commodities

BAOS

LAES

NEUP

SPRC

SVRE

ZCAR

S&P 500 Edges Lower, SciSparc Shares Surge

Paylocity Holding's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NYSE">PCTY</a>) short percent of float has fallen 25.09% since its last report. The company recently reported that it has 925 thousand shares sold short, which is 2.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Paylocity Holding Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735241421_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Paylocity Holding has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Paylocity Holding's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Paylocity Holding's peer group average for short interest as a percentage of float is 5.68%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PCTY

Looking Into Paylocity Holding's Recent Short Interest

First Solar's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NYSE">FSLR</a>) short percent of float has risen 27.67% since its last report. The company recently reported that it has 8.10 million shares sold short, which is 9.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.81 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>First Solar Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735241416_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for First Solar has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing First Solar's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, First Solar's peer group average for short interest as a percentage of float is 4.68%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FSLR

Peering Into First Solar's Recent Short Interest

Summit Materials's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) short percent of float has risen 49.37% since its last report. The company recently reported that it has 5.16 million shares sold short, which is 4.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Summit Materials Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735241410_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Summit Materials has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Summit Materials's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Summit Materials's peer group average for short interest as a percentage of float is 2.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Summit Materials's Recent Short Interest

<a href="https://downdetector.com/status/openai/" title="https://downdetector.com/status/openai/">https://downdetector.com/status/openai/</a>

MSFT

Downdetector Says User Reports Indicate Problems At OpenAi; ChatGPT, API, And Sora Is Currently Experiencing High Error Rates, Issue Caused By An Upstream Provider

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in <a href="https://www.benzinga.com/topic/weight-loss-drug">weight-loss drugs grows.</a>
What Happened: A post from Musk on Christmas shared his latest take on weight-loss drugs and could provide a suggestion to anyone<a href="https://www.benzinga.com/24/12/42291702/obesity-drug-wars-heat-up-amgen-challenges-eli-lilly-novos-dominance"> trying to decide</a> between Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic for weight-loss treatment.
The <a href="https://x.com/elonmusk/status/1872086971557761348">post </a>from Musk called himself "Ozempic Santa." Despite the post labeled with Ozempic, Musk admitted in the comments that it is actually Mounjaro that he has taken for weight-loss support.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Ozempic Santa <a href="https://t.co/7YECSNpWoz">pic.twitter.com/7YECSNpWoz</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1872086971557761348?ref_src=twsrc%5Etfw">December 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"Technically, Mounjaro, but that doesn't have the same ring to it," Musk tweeted.
Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also increasing in popularity as weight-loss options for people around the world.
When it comes to the two weight-loss drug options, Musk shared his personal takes on both.
"High doses of Ozempic made me fart &amp; burp like Barney from The Simpson's. Mounjaro seems to have fewer side effects and be more effective," Musk said.
With the Christmas posts, Musk has now shared publicly that he has tried Mounjaro, Ozempic and Wegovy, another treatment from Novo Nordisk.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/social-media/24/12/42490690/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Musk's Christmas post, continues his public support for weight-loss drugs.
After &#8220;South Park&#8221; aired a special mocking weight-loss drugs as a luxury for the wealthy, the billionaire<a href="https://www.benzinga.com/news/24/05/39019043/elon-musk-says-ozempic-will-become-very-cheap-after-new-comedy-special-paints-it-as-weight-loss-drug"> predicted these medications</a> would become more affordable over time.
In May, responding to a post about childhood obesity, <a href="https://www.benzinga.com/news/24/05/38634420/ozempic-ftw-elon-musk-touts-novo-nordisks-blockbuster-drug-as-solution-to-childhood-obesity-problem">Musk signaled support</a> for weight-loss medications by posting &#8220;Ozempic ftw&#8221; (for the win), suggesting these drugs could be a future tool against the epidemic.
The billionaire's future battle <a href="https://www.benzinga.com/general/health-care/24/12/42607280/elon-musk-vs-rfk-jr-obesity-crisis-debate-sparks-struggle-for-trumps-influence">could be convincing</a> Robert F. Kennedy Jr. and Donald Trump that Americans need more access to affordable weight-loss drugs like Mounjaro. Musk is arguing for more access while Kennedy, who Trump said will be nominated to lead the Health and Human Services, supports healthier eating to fight obesity.
NVO, LLY Price Action: Novo Nordisk stock trades at $87.56 at the time of writing. The stock is down 14% year-to-date in 2024 and up 200.6% over the last five years.
Eli Lilly stock trades at $795.87 at the time of writing. The stock is up 34% year-to-date in 2024 and up 504.7% over the last five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41036415/eli-lilly-stock-soars-in-2024-on-weight-loss-drug-success-now-the-company-wants-medical-records-o">Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments</a></li>
</ul>
Photo: Shutterstock

Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?

President-elect Donald Trump&#8216;s second term could provide for-profit prisons an economic and regulatory boon amid Trump&#8217;s plans to <a href="https://www.benzinga.com/news/24/09/40744471/trumps-plan-to-ban-mortgages-for-undocumented-immigrants-sparks-debate-what-do-the-numbers-say">deport people living in the country illegally</a>.
Private Prisons: Corecivic Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) and Geo Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) are the two largest private prison operators in the United States.
Geo Group owns 50 facilities and 64,502 beds across the U.S. concentrated in the South and Southwest. In 2023, CoreCivic operated 43 facilities with approximately 65,000 beds, according to company filings. The facilities include migrant detention centers and minimum-to-medium security prisons.
Private prisons are a topic of debate given their for-profit nature and alleged human rights abuses. <a href="https://news.uchicago.edu/story/us-prison-labor-programs-violate-fundamental-human-rights-new-report-finds">According</a> to the University of Chicago Law School, labor conditions in private prisons are poor. The majority of prisoners are forced to work, often for wages under a dollar per hour, or face solitary confinement or loss of visitation rights. The report found that prisoners produce at least $2 billion annually in goods and over $9 billion in maintenance services.
In August 2016, then-President Barack Obama announced a plan to reduce and eliminate the use of private prisons in the U.S. Following Trump&#8217;s inauguration for his first term in 2017, Attorney General Jeff Sessions rescinded Obama&#8217;s memorandum, <a href="https://www.bop.gov/resources/news/pdfs/20170224_doj_memo.pdf">saying</a> the decision &#8220;impaired the Bureau&#8217;s ability to meet the future needs of the federal correctional system.&#8221; The stock prices of Geo and CoreCivic subsequently rallied over 30%.
As of July 2024, there <a href="https://homeland.house.gov/wp-content/uploads/2024/09/24-01143-ICEs-Signed-Response-to-Representative-Tony-Gonzales.pdf">were</a> 662,566 &#8220;noncitizens&#8221; with criminal histories on ICE's national docket, which includes those detained by ICE and on the agency's non-detained docket. Of those, 435,719 are convicted criminals and 226,847 have pending criminal charges.
Trump&#8217;s Immigration Plan: Future immigration enforcement, an issue Trump made central to his 2016, 2020, and 2024 campaigns, would require detention centers, perhaps operated by Geo and CoreCivic.
The ACLU <a href="https://wp.api.aclu.org/news/immigrants-rights/unchecked-growth-private-prison-corporations-and-immigration-detention-three-years-into-the-biden-administration">found</a> in 2023 that over 90% of migrants detained by ICE were held in privately owned facilities.
In a CNN <a href="https://www.cnn.com/2024/12/18/politics/border-czar-homan-trump-deportation-plans/index.html">interview</a>, Tom Homan, Trump&#8217;s incoming border czar, said the government needs a minimum of 100,000 beds to carry out Trump&#8217;s immigration plan. This represents a more than 100% increase over current capacity. He also elaborated on the extent to which Trump will carry out deportation.
"I don't have a number. We want to arrest as many people as we can that are in the country illegally," Homan said. "If you're here illegally, you're not off the table. It's a violation of the law; it's a crime to enter this country illegally."
The American Immigration Council, a pro-immigration advocacy group, <a href="https://www.americanimmigrationcouncil.org/research/mass-deportation">says</a> there were around 11 million people living in the U.S. illegally in 2022, roughly 3% of the country&#8217;s population. The council estimates that a deportation plan would cost at least $315 billion.
Why it Matters: Geo Group and CoreCivic also appear to be preparing for the future demand for detention centers. On Dec. 16, Geo Group announced a $70 million capital expenditure plan to expand ICE service capabilities.
In September, short-seller Andrew Left <a href="https://citronresearch.com/wp-content/uploads/2024/09/Geo-Group-093024.pdf">called</a> Geo Group the &#8220;default play&#8221; for a Trump presidency given his positions on immigration enforcement.
The market at large also seems convinced. Geo Group&#8217;s stock has risen over 86% since election day, while CoreCivic&#8217;s stock has risen over 58%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42679657/el-erian-explains-why-us-economy-is-likely-to-continue-outperforming-other-major-economies-in-2025">El Erian Explains Why US Economy Is &#8216;Likely To Continue Outperforming Other Major Economies In 2025&#8217;</a></li>
</ul>
Photo via Shutterstock.

Government

Politics

CoreCivic, Geo Group Rally By Double Digits Since Election Day: Why Trump Boosts Private Prison Stocks

‘Dogecoin Killer' Shiba Inu's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) relatively flat performance over the past week has not stopped <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42173367/shiba-inu-burn-rate-soars-487-in-a-day-what-is-going-on">its burn rates from increasing</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002167</td>
<td>$12.8 billion</td>
<td>-5.2%</td>
<td>&nbsp;-2.2%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.314</td>
<td>$46.3 billion</td>
<td>-5%&nbsp;</td>
<td>-1.5%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001743&nbsp;&nbsp;</td>
<td>$7.3 billion</td>
<td>&nbsp;-5.5%</td>
<td>&nbsp;-1.2%</td>
</tr>
</tbody>
</table>
</figure>
Technical Analysis: Benzinga technical analysis shows Shiba Inu's RSI is oversold at 28.6. This suggests that the price has fallen significantly over a short period, with potential for a price rebound or reversal.
Traders may interpret an RSI below 30 as a signal to look for a buying opportunity, expecting the price to recover soon. However, technical indicators do not predict price action.
Meanwhile, the 200-day simple moving average is below the 50-day and 100-day SMAs, implying a transition from a downtrend to an uptrend. It indicates that the longer-term average price (200-day) is beginning to align with recent upward momentum, suggesting potential for sustained bullishness.
Statistics: Shibburn data shows the ecosystem burned 20.9 million SHIB in the past 24 hours, pushing the burn rate higher by 2,227.6%. 
Around 19 hours ago, a single transaction involved the burning of 13.1 million SHIB and around four hours ago, a single transaction burned 1 million SHIB coins.
Whale Alert data <a href="https://x.com/whale_alert/status/1871955035837321658">shows</a> 2.88 trillion SHIB transferred from a Turkish exchange to an unknown wallet. 
BtcTurk responded that these transfers are part of wallet optimization efforts and fully managed by them, and there is nothing out of the ordinary.
IntoTheBlock data shows large transaction volume increasing by 169.9% in a single day. Shibariumscan data shows daily transactions spiked from 4.51 million to 4.74 million in a single day.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42679813/shytoshi-kusama-celebrates-as-shibainus-virtual-world-shib-the-metaverse-goes-live-on-christmas">Shytoshi Celebrates As Shiba Inu Virtual World &#8216;Shib The Metaverse&#8217; Goes Live On Christmas</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Shiba Inu Burn Rate Spikes 2,227%: What's Going On?

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares are trading lower Thursday driven by a Bitcoin pullback and investor reaction to the company's plans to issue additional shares to <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42684275/microstrategy-portland-general-electric-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session">fund further Bitcoin purchases.</a>
What To Know: In a filing with the SEC, the company proposed increasing its authorized Class A common stock from 330 million to 10.33 billion units and preferred stock from 5 million to over 1 billion units. This move is intended to support the company's strategy of accumulating Bitcoin, a cornerstone of its transition from software to cryptocurrency investment.
Bitcoin's recent volatility, with a peak near $100,000 and subsequent fluctuations, has added pressure on MicroStrategy's stock. The company recently acquired $561 million worth of Bitcoin, bringing its total holdings to approximately $40 billion. However, its aggressive Bitcoin purchases and reliance on stock issuance to fund acquisitions have drawn investor scrutiny.
MicroStrategy shares have faced significant challenges, including a more than 37% decline from their all-time high and an 8.5% drop following their inclusion in the Nasdaq 100. The ongoing stock issuance and Bitcoin market volatility continue to weigh on investor sentiment.
MSTR Price Action: MicroStrategy shares were down 4.16% at $343.06 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="526" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-1024x526.png" alt="" class="wp-image-707953" style="width:448px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-1024x526.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-768x394.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32-1536x789.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26121816/Screenshot-2024-12-26-at-12.17.32.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42689962/a-billionaire-set-us-up-perfectly-for-this-options-trade">A Billionaire Set Us Up Perfectly for This Options Trade</a></li>
</ul>
Image Via Shutterstock.

MSTR

MicroStrategy Shares Are Falling Today: What's Going On?

Whales with a lot of money to spend have taken a noticeably bearish stance on Amentum Holdings.
Looking at options history for Amentum Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $62,908 and 10, calls, for a total amount of $599,620.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $25.0 for Amentum Holdings during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amentum Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amentum Holdings's substantial trades, within a strike price spectrum from $20.0 to $25.0 over the preceding 30 days.
<h3>Amentum Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735240536_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.7</td>
<td>$2.6</td>
<td>$2.7</td>
<td>$25.00</td>
<td>$135.0K</td>
<td>4.9K</td>
<td>2.4K</td>
</tr>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.75</td>
<td>$2.65</td>
<td>$2.7</td>
<td>$25.00</td>
<td>$112.8K</td>
<td>4.9K</td>
<td>2.9K</td>
</tr>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.5</td>
<td>$2.2</td>
<td>$2.35</td>
<td>$25.00</td>
<td>$58.7K</td>
<td>4.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.5</td>
<td>$2.2</td>
<td>$2.35</td>
<td>$25.00</td>
<td>$58.7K</td>
<td>4.9K</td>
<td>1.3K</td>
</tr>
<tr>
<td>AMTM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$2.5</td>
<td>$2.35</td>
<td>$2.35</td>
<td>$25.00</td>
<td>$58.7K</td>
<td>4.9K</td>
<td>771</td>
</tr>
</tbody>
</table>

<h3>About Amentum Holdings</h3>
Amentum Holdings Inc is engaged in engineering and technology solutions. The United States and its allies trust it to address their technical and complex scientific, security, and sustainability challenges.
Following our analysis of the options activities associated with Amentum Holdings, we pivot to a closer look at the company's own performance.
<h3>Current Position of Amentum Holdings</h3>
<ul>
<li>With a volume of 1,039,781, the price of AMTM is up 1.97% at $20.2. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 132 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amentum Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

AMTM

Check Out What Whales Are Doing With AMTM

Inozyme (INZY) Pharma announced "positive" interim data from its ongoing Phase 1 SEAPORT 1 trial of INZ-701 in patients with end-stage kidney disea...

Inozyme announces 'positive' interim data from ongoing Phase 1 SEAPORT 1 trial

An update from Inozyme Pharma ( ($INZY) ) is now available. Inozyme Pharma has announced promising interim results from its Phase 1 SEAPORT 1 trial...

Inozyme Pharma Reports Promising Results in SEAPORT 1 Trial

Inozyme Pharma (INZY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer from ...

Promising Clinical Trial Results Justify Buy Rating for Inozyme Pharma

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM – Research Report) and Inozyme Pharma (...

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Inozyme Pharma (INZY)

In a report released on October 24, Christopher Raymond from Piper Sandler maintained a Buy rating on Inozyme Pharma (INZY – Research Report), with...

Piper Sandler Sticks to Its Buy Rating for Inozyme Pharma (INZY)

TD Cowen analyst Marc Frahm has maintained their bullish stance on INZY stock, giving a Buy rating on October 25. Marc Frahm has given his Buy rati...

Promising Developments in Inozyme Pharma's INZ-701 Drive Buy Recommendation

Needham analyst Joseph Stringer has maintained their bullish stance on INZY stock, giving a Buy rating today. Joseph Stringer has given his Buy rat...

Inozyme Pharma's Strategic and Financial Positioning Bolsters Buy Rating Amid Upcoming Trial Milestones

Inozyme Pharma, Inc. ( ($INZY) ) has released its Q3 earnings. Here is a breakdown of the information Inozyme Pharma, Inc. presented to its investo...

Inozyme Pharma's Q3 2024 Financial and Clinical Progress

H.C. Wainwright analyst Edward White has reiterated their bullish stance on INZY stock, giving a Buy rating yesterday. Edward White has given his B...

Inozyme Pharma Receives Buy Rating for Promising Pipeline and Strategic Advancements

Raymond James initiated coverage of Inozyme (INZY) with an Outperform rating and $26 price target Inozyme is developing INZ-701, a biologic analog ...

Inozyme initiated with an Outperform at Raymond James

DXCM

Press Releases

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

Earnings

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting

Management

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma to Present at Upcoming Investor Conferences

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Alector

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Inozyme Pharma

Inozyme Pharma (INZY) Forecast

Inozyme Pharma (NASDAQ:INZY) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga